Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Terbinafine often takes weeks to months to show visible results, especially for toenail fungus, because the medication works as new, healthy nail or skin grows in, and slow nail growth, thick nails, poor circulation, diabetes, missed doses, or reinfection from shoes, floors, and untreated household members can all stall progress. In some cases the culprit is not a dermatophyte at all but yeast, a nondermatophyte mold, psoriasis, eczema, or nail trauma, none of which respond well to terbinafine, and true drug resistance is now increasingly reported. There are several important factors that determine whether you should keep waiting, switch to a different antifungal, or get testing such as a KOH prep or fungal culture, so see below to understand more before you stop or continue treatment. Because "failed" antifungal therapy so often means the wrong diagnosis, the wrong duration, or an ongoing source of reinfection, sorting out which applies to you is the fastest way to finally clear it. Take a free, instant, online symptom check to help clarify what may be driving your persistent symptoms and to understand which next steps and specialist conversations make the most sense for you.
Last reviewed for medical accuracy: 09/12/2026
Terbinafine is a widely used antifungal agent for skin infections (like athlete’s foot and ringworm) and nail fungus (onychomycosis). Yet, some people see little or no improvement even after several weeks of treatment. Understanding why terbinafine might not be effective can help you take the right next steps.
Terbinafine stops fungi from making ergosterol, a vital component of their cell membranes. Without ergosterol, the fungal cells weaken and die. Depending on the type of infection, terbinafine can be applied as a cream or taken as an oral tablet.
Even with the correct drug, fungal infections—especially nail infections—require patience. Nails grow slowly, and it can take several months for a new, healthy nail to replace the infected portion.
Fungal infections can look like other skin or nail conditions, such as psoriasis, eczema, or bacterial infections. If your issue isn’t truly fungal, terbinafine won’t help.
Signs to consider:
If you stop too early or skip doses, fungal cells can survive, leading to a rebound of infection.
Some medications alter how your body processes terbinafine, reducing its blood levels.
Common offenders include:
Always tell your doctor about every prescription, over-the-counter medicine, and supplement you take.
While many dermatophytes respond well to terbinafine, non-dermatophyte molds and yeast (like Candida) may be less sensitive. A lab culture or biopsy can identify the exact culprit and guide treatment.
Fungus thrives in warm, moist places. Even if you clear the infection on your feet, you could pick it up again if you:
Certain health issues can make fungal infections harder to treat:
If you have any chronic disease or take immune-modulating drugs, terbinafine alone may not be enough.
Review your regimen
Improve local treatment
Address environmental risks
Consider medical evaluation
Look at your overall health
Even mild fungal infections can become serious if left unchecked. See a doctor promptly if you notice:
For a quick check of your symptoms, you might try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Terbinafine is a powerful antifungal, but it’s not foolproof. Factors such as misdiagnosis, poor absorption, resistant organisms, and lifestyle habits can all limit its success. By reviewing your treatment plan, managing risk factors, and getting the right tests, you can improve your chances of clearing the infection.
Above all, if you experience worsening symptoms or anything that could be life threatening or serious, speak to a doctor right away. Your health and safety come first.
(References)
* Skaastrup KN, Astvad KMT, Arendrup MC, Jemec GBE, Saunte DML. Disinfection trials with terbinafine-susceptible and terbinafine-resistant dermatophytes. Mycoses. 2022 Jul;65(7):741-746. doi: 10.1111/myc.13468. PMID: 35535729; PMCID: PMC10138727.
* Durdu M, Kandemir H, Karakoyun AS, Ilkit M, Tang C, de Hoog S. First Terbinafine-Resistant Trichophyton indotineae Isolates with Phe(397)Leu and/or Thr(414)His Mutations in Turkey. Mycopathologia. 2023 Jan 19;188(1):2. doi: 10.1007/s11046-023-00708-2. Epub 2023 Jan 19. PMID: 36656402.
* Zaraa I, Dehavay F, Richert B. Onychomycosis. Hand Surg Rehabil. 2024 Apr;43S:101638. doi: 10.1016/j.hansur.2024.101638. Epub 2024 Jan 11. PMID: 38218374.
* Gupta AK, Mann A, Polla Ravi S, Wang T. An update on antifungal resistance in dermatophytosis. Expert Opin Pharmacother. 2024 Apr;25(5):511-519. doi: 10.1080/14656566.2024.2343079. Epub 2024 Apr 17. PMID: 38623728.
* Gupta AK, Wang T, Mann A, Polla Ravi S, Talukder M, Lincoln SA, Foreman HC, Kaplan B, Galili E, Piguet V, Shemer A, Bakotic WL. Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections. Expert Rev Anti Infect Ther. 2024 Sep;22(9):739-751. doi: 10.1080/14787210.2024.2390629. Epub 2024 Aug 18. PMID: 39114868.
* Barac A, Stjepanovic M, Krajisnik S, Stevanovic G, Paglietti B, Milosevic B. Dermatophytes: Update on Clinical Epidemiology and Treatment. Mycopathologia. 2024 Nov 21;189(6):101. doi: 10.1007/s11046-024-00909-3. Epub 2024 Nov 21. PMID: 39567411.
* Shao Y, Shao J, de Hoog S, Verweij P, Bai L, Richardson R, Richardson M, Wan Z, Li R, Yu J, Song Y. Emerging antifungal resistance in Trichophyton mentagrophytes: insights from susceptibility profiling and genetic mutation analysis. Emerg Microbes Infect. 2025 Dec;14(1):2450026. doi: 10.1080/22221751.2025.2450026. Epub 2025 Jan 15. PMID: 39749731; PMCID: PMC11740296.
* Svendsen MB, Astvad KMT, Hald M, Andersen SML, Henning MAS, Andersen PL, Blomberg M, Saunte DML. [Recalcitrant dermatophytosis]. Ugeskr Laeger. 2025 Mar 31;187(14). doi: 10.61409/V09240659. Epub 2025 Mar 31. PMID: 40171909.
* Xie W, Liang G, Kong X, Tsui CKM, She X, Liu W, Li X. Genomic epidemiology and antifungal resistance of emerging Trichophyton indotineae in China. Emerg Microbes Infect. 2025 Dec;14(1):2498571. doi: 10.1080/22221751.2025.2498571. Epub 2025 May 12. PMID: 40293476; PMCID: PMC12077451.
* Er YX, Lee SC, Aneke C, Conlan S, Muslim A, Deming C, Che Y, Yap NJ, Tee MZ, Abdull-Majid N, Shahrizal S, Leong KF, Han J, Shen Z, Than LTL, Park M, Mohd Sayed I, NISC Comparative Sequencing Program, Seyedmousavi A, Kong HH, Loke P, Segre JA, Lim YAL. Trichophyton concentricum fungal infections and skin microbiomes of Indigenous Peninsular Malaysians. Cell. 2025 Aug 7;188(16):4257-4274.e13. doi: 10.1016/j.cell.2025.05.034. Epub 2025 Jun 17. PMID: 40532696; PMCID: PMC12335371.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.